导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.26% | 1437/4773 |
| 近一周 | -2.48% | 3928/5465 |
| 近一月 | -3.81% | 2822/5421 |
| 近一季 | -3.56% | 1639/5231 |
| 近半年 | -1.16% | 1702/4920 |
| 近一年 | 8.30% | 1346/4394 |
| 近两年 | 52.63% | 1428/2954 |
| 近三年 | 37.06% | 838/2253 |
| 成立以来 | 217.49% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.80% 1179/4961 |
6.13% 2849/5312 |
- - |
- - |
| 2025 | 23.24% 1892/4813 |
-2.16% 2851/3635 |
1.52% 2297/4076 |
22.70% 1620/4524 |
1.12% 1520/4813 |
| 2024 | 13.47% 1135/3463 |
5.34% 370/2808 |
0.06% 651/3014 |
11.31% 2531/3129 |
-3.29% 2317/3463 |
| 2023 | -1.18% 497/2656 |
8.71% 448/2280 |
-1.26% 464/2385 |
-3.00% 821/2515 |
-5.09% 1254/2655 |
| 2022 | -15.36% 417/2207 |
-10.13% 378/1919 |
6.77% 608/2016 |
-11.59% 548/2113 |
-0.22% 1577/2208 |
| 2021 | 8.45% 477/1822 |
0.64% 280/1255 |
4.46% 884/1330 |
2.85% 426/1466 |
0.31% 1138/1822 |
| 2020 | 46.53% 209/1250 |
-2.30% 258/1028 |
15.41% 504/1067 |
14.80% 255/1164 |
13.20% 381/1184 |
| 2019 | 34.26% 410/1092 |
26.00% 432/754 |
-2.54% 356/804 |
2.69% 291/850 |
6.46% 607/918 |
| 2018 | -25.44% 351/834 |
- - |
- - |
- - |
-14.10% 569/691 |
| 2017 | 23.44% 136/714 |
- - |
- - |
- - |
- - |
| 2016 | -8.39% 245/605 |
- - |
- - |
- - |
- - |
| 2015 | 8.48% 168/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 汇添富沪深300安中指数A VS. 长安沪深300非周期A(740101) |